5-Aminosalicylic acid-d7

5-Aminosalicylic acid-d7

• UNSPSC Description: 5-Aminosalicylic acid-d7 (5-ASA-d7; Mesalamie-d7; Mesalazie-d7) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN)[1].
• Target Antigen: Endogenous Metabolite; Isotope-Labeled Compounds; NF-κB; PAK; PPAR
• Type: Isotope-Labeled Compounds
• Related Pathways: Cell Cycle/DNA Damage;Cytoskeleton;Metabolic Enzyme/Protease;NF-κB;Others;Vitamin D Related/Nuclear Receptor
• Field of Research: Inflammation/Immunology;Cancer
• Smiles: [2H]C1=C(C(O[2H])=C(C([2H])=C1N([2H])[2H])[2H])C(O[2H])=O
• Molecular Weight: 160.18
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Rousseaux C, et al. The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ. Carcinogenesis. 2013 Nov;34(11):2580-6.|[3]Dammann K, et al. PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation. Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2349-60.|[4]Fang HM, et al. 5-aminosalicylic acid in combination with Nimesulide inhibits proliferation of colon carcinoma cells in vitro. World J Gastroenterol. 2007 May 28;13(20):2872-7.|[5]Ramadan A, et al. Mesalazine, an osteopontin inhibitor: The potential prophylactic and remedial roles in induced liver fibrosis in rats. Chem Biol Interact. 2018 Jun 1;289:109-118.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported